The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMorgan Advanced Materials Regulatory News (MGAM)

Share Price Information for Morgan Advanced Materials (MGAM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 306.00
Bid: 305.50
Ask: 306.50
Change: 3.50 (1.16%)
Spread: 1.00 (0.327%)
Open: 300.00
High: 306.50
Low: 300.00
Prev. Close: 302.50
MGAM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q3 Trading Update

9 Nov 2023 07:00

RNS Number : 8547S
Morgan Advanced Materials PLC
09 November 2023
 

 

 

Press Release

Morgan Advanced Materials plc

9 November 2023

 

Trading Update

Strong financial position, growth outlook unchanged

Morgan Advanced Materials plc, the global manufacturer of advanced carbon and ceramic materials for technically demanding applications, announces today its scheduled trading update for the first nine months to 30 September 2023.

Current Trading

Sales for the nine months to September 2023 were 2.4% higher for the Group, on an organic constant-currency basis, compared with the same period last year. Our recovery from the cyber incident we experienced at the start of the year has progressed as planned. By business unit, organic constant-currency sales performance for the nine months to September 2023, compared with the same period last year, were as follows:

 

Thermal Ceramics

+0.9%

Molten Metal Systems

-7.2%

Electrical Carbon

+6.5%

Seals and Bearings

-5.4%

Technical Ceramics

+7.7%

 

Outlook

Our outlook for full year organic revenue growth is unchanged at 2-4%. The group has continued to benefit from strong growth in its Semiconductor, Healthcare and Aerospace end-markets, offsetting weakness in European and China industrial markets. Seals & Bearings performance was influenced in part by phasing of armour orders.

Margins have continued to improve sequentially, despite an adverse movement in FX impacting the second half by circa £3m.

We continue to pursue opportunities to remove cost to ensure we enter 2024 with the right cost structure. Although uncertainty remains around some of our end markets, looking forward we expect continued margin improvement and good growth in H1 2024, especially given the cyber incident in the comparative period. In particular, we expect sustained growth in Semiconductor driven by demand for Silicon Carbide applications in power electronics.

 

Pete Raby, Chief Executive Officer, said:

"Our business is growing as anticipated, benefitting from our leading, differentiated positions in selected markets and despite the challenging environment, with inflation continuing to be more than offset by pricing.

Our Board remains committed to our financial framework. Investment in capacity for our faster growing segments is accelerating, and we continue to investigate inorganic investments as well as consider opportunities for enhanced returns to shareholders."

The full year results are expected to be released on 14 March 2024. A Capital Markets Event will be held during Q2 2024, with updates on progress in our faster growing markets, opportunities for efficiency improvement and investment plans.

 

For further enquiries:

Pete Raby

Morgan Advanced Materials plc

01753 837000

Richard Armitage

Nina Coad

Brunswick

0207 404 5959

 

1. Company-compiled summary of current analysts' forecasts for adjusted operating profit for 2023 is a range of £120.5 million to £125.0 million.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTEAPFPEEDDFFA
Date   Source Headline
24th Apr 20247:00 amRNSCapital Markets Update
5th Apr 202412:55 pmRNSAnnual Financial Report
4th Apr 20241:16 pmRNSDirector/PDMR Shareholding
27th Mar 20244:52 pmRNSDirector/PDMR Shareholding
27th Mar 20244:50 pmRNSDirector/PDMR Shareholding
27th Mar 20244:49 pmRNSDirector/PDMR Shareholding
27th Mar 20244:48 pmRNSDirector/PDMR Shareholding
14th Mar 20249:42 amRNSDirector/PDMR Shareholding
14th Mar 20249:41 amRNSDirector/PDMR Shareholding
13th Mar 202412:10 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSMorgan Advanced Materials Full Year 2023 Results
27th Dec 20237:00 amRNSDirector/PDMR Shareholding
19th Dec 20231:56 pmRNSDirector/PDMR Shareholding
18th Dec 20234:25 pmRNSBlock listing Interim Review
22nd Nov 202310:07 amRNSDirector/PDMR Shareholding
9th Nov 20237:00 amRNSQ3 Trading Update
9th Oct 20234:43 pmRNSDirector/PDMR Shareholding
26th Sep 202312:24 pmRNSDirector/PDMR Shareholding
16th Aug 202311:27 amRNSDirector/PDMR Shareholding
7th Aug 20235:24 pmRNSDirector/PDMR Shareholding
4th Aug 20237:00 amRNSHalf-Year Results for Period Ended 30 June 2023
13th Jul 20234:49 pmRNSDirector/PDMR Shareholding
5th Jul 20234:51 pmRNSDirector/PDMR Shareholding
29th Jun 20235:06 pmRNSResult of AGM
29th Jun 20237:00 amRNSH1 Trading Update
22nd Jun 202311:50 amRNSBlock listing Interim Review
31st May 20233:52 pmRNSDirector/PDMR Shareholding
26th May 20233:28 pmRNSNotice of Annual General Meeting 2023
24th May 20233:59 pmRNSDirector/PDMR Shareholding
11th May 202312:06 pmRNSDirector/PDMR Shareholding
11th May 202312:01 pmRNSDirector/PDMR Shareholding
11th May 202311:59 amRNSDirector/PDMR Shareholding
9th May 20235:59 pmRNSDirector/PDMR Shareholding
4th May 20235:28 pmRNSAnnual Report & Accounts 2022
3rd May 20235:38 pmRNSDirector/PDMR Shareholding
3rd May 20235:28 pmRNSDirector/PDMR Shareholding
28th Apr 20235:45 pmRNSInformation required by DTR 4.1
28th Apr 20237:00 amRNSFull-year results for the period ended 31 Dec 2022
13th Apr 20237:00 amRNSNotification of Full-Year Results
7th Feb 20237:00 amRNSUpdate on Trading and Cyber Security Incident
18th Jan 20237:00 amRNSAppointment of Chair Designate
10th Jan 20237:00 amRNSNotice of Cyber Security Incident
22nd Dec 202211:01 amRNSBlock listing Interim Review
16th Dec 20224:44 pmRNSHolding(s) in Company
6th Dec 20227:00 amRNSAccelerated Pension Contribution
6th Dec 20227:00 amRNSCapital Markets Event
23rd Nov 202210:01 amRNSDirector/PDMR Shareholding
15th Nov 20225:06 pmRNSDirector/PDMR Shareholding
10th Nov 20228:03 amRNSDirector Declaration
4th Nov 20227:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.